DocWire News Editors

DocwireNews

The Revised International Prognostic Scoring System (IPSS-R) is a useful tool to predict clinical outcomes in patients with myelodysplastic syndromes (MDS), and it often guides clinicians and patients when they make treatment decisions.The IPSS-R stratifies patients with MDS into five risk groups: very low, low, intermediate, high, and very high. A group of researchers from Spain said that because treatment decisions are often based on whether patients are low risk or high risk, they wanted more clarity regarding cutoffs and treatment decisions in the intermediate-risk group.They conducted a study to determine the specific point on the IPSS-R that best divides patients into low versus high risk, as well as explore clinical characteristics and outcomes in patients labeled as intermediate risk.The study included all patients diagnosed with MDS between 1980 and 2019 who were in the Spanish Registry of Myelodysplastic Syndromes with all of the variables needed to be classified according to the IPSS-R. The total sample was 4,103.The researchers calculated prognostic risk according to the IPSS-R, and they defined low risk as those who ultimately had overall survival (OS) of 30 months or more.Median follow-up for patients who survived was 52.7 months, and median OS was 52.9 months. The researchers found that the IPSS-R cutoff that best identified low-risk disease was 3.5 or lower. This was defined as 75% accuracy predicting OS of 30 months or longer. In the current sample, that equated 2,830 patients (69%) with low-risk disease and 1,273 (31%) with high-risk disease, with median OS rates of 75 months and 15.4 months, respectively.With the cutoff set at 3.5, most of the patients in this sample who would have been classified as intermediate risk were upgraded to high risk (n=457/706; 65%). In this study, the intermediate-risk group had clinical outcomes that were more similar to patients with high-risk MDS than low-risk MDS, such as lower OS and more risk of transformation into acute myeloid leukemia.&ldquo;By using this cutoff, most patients with intermediate-risk MDS according to the IPSS-R are indeed considered as higher risk,&rdquo; said lead presenter Maria Julia Montoro, MD, PhD, of the Department of Hematology at Vall d&rsquo;Hebron Hospital Universitari in Barcelona, Spain. &ldquo;These findings have relevant clinical implications, as they imply that intermediate-risk patients should be managed as high-risk MDS.&rdquo;

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Study Defines Cutoff to Stratify Patients with Intermediate Risk According to IPSS-R

ASH Annual Meeting 2020

The Revised International Prognostic Scoring System (IPSS-R) is a useful tool to predict clinical outcomes in patients with myelodysplastic syndromes (MDS), and it often ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe